News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GroPep Limited Changes Track From Psoriasis Drug To Asthma
December 14, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Following poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Australia
MORE ON THIS TOPIC
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
February 6, 2026
·
4 min read
·
Mark Zipkin
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
February 4, 2026
·
2 min read
·
Heather McKenzie
